Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) - PubMed (original) (raw)
Practice Guideline
. 2018 Dec;41(12):2669-2701.
doi: 10.2337/dci18-0033. Epub 2018 Oct 4.
Affiliations
- PMID: 30291106
- PMCID: PMC6245208
- DOI: 10.2337/dci18-0033
Practice Guideline
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J Davies et al. Diabetes Care. 2018 Dec.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.
© 2018 American Diabetes Association and European Association for the Study of Diabetes.
Figures
Figure 1
Decision cycle for patient-centered glycemic management in type 2 diabetes.
Figure 2
Glucose-lowering medication in type 2 diabetes: overall approach. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.
Figure 3
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.
Figure 4
Choosing glucose-lowering medication if compelling need to minimize weight gain or promote weight loss. GLP-1 RA, glucagon-like peptide 1 receptor agonist; T2DM, type 2 diabetes; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.
Figure 5
Choosing glucose-lowering medication if compelling need to minimize hypoglycemia. DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor.
Figure 6
Choosing glucose-lowering medication if cost is a major issue. DPP-4i, dipeptidyl peptidase 4 inhibitor; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.
Figure 7
Intensifying to injectable therapies. FRC, fixed-ratio combination; GLP-1 RA, glucagon-like peptide 1 receptor agonist; FBG, fasting blood glucose; FPG, fasting plasma glucose; max, maximum; PPG, postprandial glucose.
Figure 8
Considering oral therapy in combination with injectable therapies. DKA, diabetic ketoacidosis; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.
Comment in
- Comment on the consensus report on the management of hyperglycaemia in Type 2 diabetes by the American Diabetes Association and the European Association for the Study of Diabetes.
Skinner T, Byrne M, Dickinson JK, Fisher L, Funnell M, Guzman S, Hendrieckx C, Hermanns N, Kanc K, Lloyd C, Mocan A, Nouwen A, Pouwer F, Saleh-Stattin N, Snoek F, Speight J, Sturt J, Vallis M, Wagner J, Willaing I, Young-Hyman D, Zoffmann V. Skinner T, et al. Diabet Med. 2019 Jul;36(7):911-912. doi: 10.1111/dme.13934. Epub 2019 Apr 3. Diabet Med. 2019. PMID: 30785642 No abstract available.
Similar articles
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Davies MJ, et al. Diabetologia. 2018 Dec;61(12):2461-2498. doi: 10.1007/s00125-018-4729-5. Diabetologia. 2018. PMID: 30288571 - 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D'Alessio DA, Davies MJ. Buse JB, et al. Diabetes Care. 2020 Feb;43(2):487-493. doi: 10.2337/dci19-0066. Epub 2019 Dec 19. Diabetes Care. 2020. PMID: 31857443 Free PMC article. - Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Davies MJ, et al. Diabetologia. 2022 Dec;65(12):1925-1966. doi: 10.1007/s00125-022-05787-2. Epub 2022 Sep 24. Diabetologia. 2022. PMID: 36151309 Free PMC article. Review. - Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Davies MJ, et al. Diabetes Care. 2022 Nov 1;45(11):2753-2786. doi: 10.2337/dci22-0034. Diabetes Care. 2022. PMID: 36148880 Free PMC article. Review.
Cited by
- Evaluating Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes Mellitus: A Systematic Review.
Sreenivasan C, Parikh A, Francis AJ, Kanthajan T, Pandey M, AlQassab O, Nath TS. Sreenivasan C, et al. Cureus. 2024 Aug 12;16(8):e66697. doi: 10.7759/cureus.66697. eCollection 2024 Aug. Cureus. 2024. PMID: 39262558 Free PMC article. Review. - Unveiling the Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review.
Rajagopal D, Al Rashid S, Prasad M, Fareed M. Rajagopal D, et al. Cureus. 2024 Jul 31;16(7):e65910. doi: 10.7759/cureus.65910. eCollection 2024 Jul. Cureus. 2024. PMID: 39219906 Free PMC article. Review. - Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex-sumo wrestler.
Bade S, Bade S, Sharma G, Bhurtel N, Singh Y, Paudel S, Magar FP, Chapagain K. Bade S, et al. Clin Case Rep. 2024 Aug 29;12(9):e9403. doi: 10.1002/ccr3.9403. eCollection 2024 Sep. Clin Case Rep. 2024. PMID: 39219781 Free PMC article. - Glucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes.
Sjöholm Å. Sjöholm Å. BMJ Open Diabetes Res Care. 2024 Aug 30;12(4):e004291. doi: 10.1136/bmjdrc-2024-004291. BMJ Open Diabetes Res Care. 2024. PMID: 39214626 Free PMC article. Review. - A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects.
Acosta G AJ, Chitneni E, Manzanares Vidals CJ, Modumudi S, Hammad S, Verma A, Rajesh RY, Khaliq A, Adeyemi O, Majeed F, Gujar RV. Acosta G AJ, et al. Cureus. 2024 Jul 29;16(7):e65707. doi: 10.7759/cureus.65707. eCollection 2024 Jul. Cureus. 2024. PMID: 39211720 Free PMC article. Review.
References
- Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS, et al. . Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol 2016;4:706–716 - PubMed
- American Diabetes Association 6. Glycemic targets: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1):S55–S64 - PubMed
- American Diabetes Association 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1):S73–S85 - PubMed
- Inzucchi SE, Bergenstal RM, Buse JB, et al. .; Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) . Management of hyperglycaemia in type 2 diabetes a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577–1596 - PubMed
- Inzucchi SE, Bergenstal RM, Buse JB, et al. . Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429–442 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials